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  EVIDENCE-BASED ANSWER 
Propranolol, valproic acid, and amitriptyline are effective prophylaxis for migraine in children to varying 
degrees, are widely available, and have a reasonable safety profile (strength of recommendation [SOR]: B, 
based on either single randomized controlled trial, prospective or retrospective cohort studies, or trials with 
conflicting evidence). 
Flunarizine and nimodipine have the best evidence of benefit in children; however, availability, cost, and side 
effects limit their usefulness (SOR: B, based on multiple small randomized controlled trials). 
  EVIDENCE SUMMARY 
Amitryptyline was moderately efficacious in 3 small nonblinded trials.1,2 The largest and best-designed 
prospective cohort trial studied 192 children. Of the 146 patients available for the first follow-up visit, 84% noted 
subjective improvement of symptoms. Headache frequency decreased from 17.1 ± 10.1 to 9.2 ± 10.0 
days/month (P<.001).1 
Propranolol, although widely used in children, has conflicting evidence regarding effectiveness. One small 
randomized controlled trial showed reduced headache frequency in children when compared with placebo.3 
However, these results were not duplicated in a larger randomized controlled trial using slightly smaller doses.4 
A comparative randomized controlled trial with multiple crossovers involving 33 children found that a self-
hypnosis placebo decreased mean headache frequency from 13.3 per 3-month interval to 5.8 (P=.045), but 
found propranolol no different than placebo.5 Propranolol was also studied in a 3-armed randomized controlled 
trial in comparison with flunarizine—a drug likely to be efficacious—and placebo. Both drugs were equally 
efficacious and superior to placebo according to reviews; however, these results were not published in English 
and could not be critiqued by this author.2 
In 2 small retrospective case studies, valproic acid demonstrated >50% improvement in symptoms in 65%6 and 
78%7 of subjects. A single uncontrolled interventional trial of valproic acid in 10 children showed a significant 
trend of improvement in frequency (mean of 6 attacks/month to 0.8 attacks/month) and duration (mean 5.5 
hours per attack to 1.1 hour).8 
Two similar vasodilatory calcium channel blockers, flunarizine and nimodipine, have the best evidence as 
migraine prophylactics in children. Flunarizine was found to be effective in multiple well-designed randomized 
controlled trials and case series, as well as in multiple comparative trials with other agents.2 
In a double-blinded, placebo-controlled randomized controlled trial of 48 children, flunarizine decreased mean 
headache frequency (3.0 attacks/3 months vs 6.5 [P<.001]).9 A repeat randomized controlled trial in 70 
children had similar outcomes.10 
Nimodipine, in a single randomized controlled trial with crossover design in 37 children decreased headache 
frequency from a mean of ~2.7 attacks/month to ~1.9 vs. no change for placebo (P<.05).11 A small, 
prospective, nonblinded comparative trial found that nimodipine and flunarizine have similar efficacy and are 
superior to placebo.12 
Cyproheptadine is widely used in children but is not as effective as amitriptyline and propranolol.2 In adults it is 
not considered a first-line agent due to lack of evidence of efficacy.13 Nonsteroidal anti-inflammatory drugs 
have insufficient data to recommend them as prophylactic medications in children.2 
  RECOMMENDATIONS FROM OTHERS 
Nelson Textbook of Pediatrics recommends propranolol as a first-line agent for prevention.14 
A recent review article15 recommends cyproheptadine as an initial agent in children <10 years of age. This 
article also has a patient handout discussing nonpharmacologic prophylactics such as regular sleep, exercise, 
stress reduction, and avoiding certain foods. 
UpToDate recommends propranolol, cyproheptadine, valproate, and amitriptyline as prophylactic options 
based on patient parameters such as age, sex, and comorbid conditions.16 
CLINICAL COMMENTARY 
Propranolol has fewest side effects 
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Migraines in children are not as well studied as the same problem in adults. I like to stick 
with older medications known to have fewer side effects. Propranolol is my first choice for 
any age, since it has been well studied and has very few side effects. Amitriptyline would 
be second because it is well known, but it does have a sedating effect. If both of these fail 
to control the migraines, I would consider calcium channel blockers, which are newer in 
the prevention of migraines. 
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